If you're looking the next up-and-coming stocks then look no further than Cabot Small-Cap Confidential. We limit the circulation of our advisory so that our subscribers own the stocks before the big institutions start buying them.
Each month Chief Analyst Thomas Garrity will present a new small-cap stock with his in-depth research. You'll see many stocks from emerging technologies, including mobile telecommunications, biotech, cyber security, genetic medicine, bio-pharmaceuticals, sensors, robotics and other fields with unlimited upside potential.
Cabot Small-Cap Confidential's focus is on finding undervalued and little-known small-cap companies with big ideas that serve very large markets. The advisory recommends one stock each month, and usually holds them as long-term investments. The advisory does not present a model portfolio—i.e., there's no cash position, weightings, etc.; however, all recommendations are followed up weekly with buy, hold and eventually sell ratings.The performance shown is the average gain of Cabot Small-Cap Confidential stocks since inception on 10/8/07, excluding current holdings as of 6/29/15.
235% in Baxano Surgical
187% in Ovascience
148% in Cardiovascular Systems
116% in Cerus
Navgiate the fast-paced world of small-cap stocks with Cabot Small-Cap Confidential. This limited-circulation advisory will help you find the technologies of tomorrow, with virtually limitless profit opportunities.
Sign up now for a risk-free trial subscription to Cabot Small-Cap Confidential. If you don’t like it, you'll receive a pro-rated refund.
What our Customers say about Small-Cap Confidential
I can't thank you enough for making such great recommendations, I love reading your newsletters.
D. Napoletano, DMD, Middletown, New York
It has been an exhausting search to find an advisory service as good as Cabot Small-Cap Confidential. The proof is in the pudding.
J. Cramer, Topeka, Kansas
I just simply want to thank you for your efforts and stellar analysis work. As you may know, I am a charter subscriber to Cabot Small-Cap Confidential. While things seemed bleak towards the end of 2008, I am happy to say that my small cap portfolio, initiated in Fall of 2007, has now grown to $215,760, and of that total, $41,117 is profit. Given what the markets and the economy have been through during 2008, I believe this is a very good result. I have ended up committing more funds to the portfolio than I had planned, mostly because I have reinvested profits from partial sales of stocks such as UQM and BDSI. In addition, my large cap portfolio, which was initiated in Jan of 2009, has been very profitable as well, and I have moved some of those profits into the small cap stocks. All in all, it is very exciting to see this approach start to come together, and I am very optimistic about what the future holds. Once again, thanks very much for your great work, and thanks also for your past comments and help on my portfolio.
Daniel, Salt Lake City, Utah
Are you ready to get started with your risk-free trial subscription?